| abstract |
Novel 4,5-azolo-oxindoles with formula (I) (such as: 8- (3-methoxy-1H-pyrrol-2-ylmethylene) -2-phenyl-6,8-dihydroxo-oxazolo [4 , 5e] indole-7-one) where R1 is H, OR3, COR3, COOR3, CONR4R5, NR4R5, lower alkyl, cycloalkyl, heterocycle, aryl, etc; R2 is selected from H, OR3, NR4R5, halogen, COR3, COOR3, OCOR ยท, CONR4R5, CN, optionally substituted lower alkyl; X means = N or = C (R5); Y and Z are each independently N, O, or S; Considering that at least one of Y and Z is N, and if both are N then they can be substituted by lower alkyl since it is a double bond between YC or ZC, they inhibit cyclin-dependent kinases (CDKs), in particular CDK2, and they are useful in the treatment or control of cell proliferative disorders, in particular cancer. A pharmaceutical composition containing as an active ingredient a compound of formula I and a pharmaceutically acceptable carrier or excipient. |